Organon & Co | OGN - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Celltrion KRW 434.82B 1.14B 2026-03
Cspc Pharmaceutical CNY 33.18B 71.46M 2025-12
Deva Holding AS TRY 5.79B 604.07M 2023-09
Dianthus Therapeutics USD 1.17B 29.29M 2026-06
Divis Laboratories Ltd INR 167.61B 13.48B 2026-03
Gilead Sciences USD 11.74B 11.77B 2026-06
Glaxosmithkline GBP 17.42B 4.64B 2026-03
Kangmei Pharma CNY 7.31B 84.82M 2026-03
Knight Therapeutics CAD 767.27M 480K 2025-12
Laboratorios Farma EUR 539.39M 22.74M 2023-12
Malin Corporation EUR 193.2M 75M 2024-12
Medical Developments International AUD 54.77M 335K 2025-12
Merck USD 41.93B 3.94B 2026-06
Neuren Pharmaceuticals AUD 338.45M 15.18M 2025-12
Novartis USD 38.93B 7.2B 2026-03
Organigram Holdings CAD 371.81M 2.36M 2026-03
Organon & Co USD 1.01B 103M 2026-06
Ovoca Bio EUR 780K 485K 2025-12
Pharma Mar EUR 250.77M 1.1M 2026-06
Qiagen NV USD 3.36B 26.03M 2026-06
Sartorius EUR 2.82B 96.3M 2026-06
Sino Biopharmaceutical CNY 34B 1.48B 2025-06
Tilray USD 1.58B 39.08M 2025-09
Zealand Pharma A/S 14.47B 361.61M 2026-03